 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| ONCX Initiates Important New Research with Cancer Research Leader MD Anderson |
|
 Hot Stock to Watch |
Company: Oncolix, Inc. (OTCQB: ONCX)
|
Last:
Price: 0.0443
Change (%): + 0.00 (0.00)
Volume: 0 |
 |
Oncolix Sponsors Additional Research with MD Anderson Cancer Center
Research to Evaluate Prolanta™ for Uterine Cancer
HOUSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) - Oncolix, Inc., (OTCQB:ONCX) announced today that the Company has sponsored additional research with MD Anderson Cancer Center. The research will evaluate ProlantaTM for the potential treatment of additional gynecological cancers, in particular uterine cancer. Previous research funded at the MD Anderson Cancer Center resulted in the discovery of the mechanism of action of ProlantaTM (autophagy) and preclinical evidence of efficacy in ovarian cancer.
“Because Prolanta has the potential to treat all gynecological cancers, it is only fitting that we expand our focus to uterine cancer,” said Michael T. Redman, chief executive officer of Oncolix. “Like ovarian cancer, more than 80% of uterine cancer cells overexpress prolactin receptors, which are the molecular target for ProlantaTM. Similarly, the unmet medical needs for uterine cancer are similar to ovarian cancer.”
Prolanta™ is being evaluated in an open-label dose escalation Phase 1 clinical trial in patients with advanced ovarian cancer. Patients are divided into three dosing groups, or cohorts. Each sequential cohort will evaluate a higher dose of Prolanta™. Patients will be evaluated over a 99-day period. Initial dosing for 28 days is followed by a two-week safety assessment period, and then continues for an additional 56 days if no toxicities are observed. The first cohort, treated with the lowest dose, was completed, and has shown no serious adverse events or dose-limiting toxicity. Earlier this January, the Company announced it is now recruiting the mid-dose patients for this trial. For more information about the Phase 1 clinical trial please visit: https://clinicaltrials.gov/ct2/show/NCT02534922?term=Prolanta&rank=1
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
